Jaguar Health Stock Soars 35% After Hours - Jaguar Health (NASDAQ:JAGX)
Jaguar Health (NASDAQ:JAGX) shares surged 34.67% to $6.37 in after-hours trading. The company declared a special dividend of Series R Convertible Preferred Stock, convertible into common shares. It also extended debt payments to 2027. JAGX has a market cap of $9.20 million and an RSI of 45.39, trading near its yearly low.
How this was made
The 30-second read
Why it matters
The announcement of a special dividend and debt payment deferment sparked a 35% after‑hours rally, but the upcoming conversion of preferred shares could dilute existing shareholders.
Market read
The news provides fresh corporate‑action information that moved the stock sharply, offering a short‑term trading opportunity but also indicating future dilution risk.
What to watch
Liquidity risk from high trading volume and the small market cap may amplify price swings; investors should watch for further guidance on cash flow.
Background
Jaguar Health (JAGX) is a California‑based commercial‑stage pharmaceutical firm with a market cap of roughly $9 million.
Ticker impact
Jaguar Health announced a 34.67% after‑hours price jump and a special Series R convertible preferred dividend that will convert into common shares, plus deferred debt payments to 2027.
potential short‑term upside from momentum, followed by downside pressure from dilution after conversion.
The move is driven by a fresh corporate action (special dividend and debt deferment). Momentum traders may act now, but the conversion terms suggest future dilution risk.
Market effects
Highlights financing flexibility in micro‑cap pharma, may prompt peers to consider similar preferred‑share structures.
Limited to U.S. micro‑cap investors; no broader regional effect.
Low; the news is company‑specific and does not affect global markets.
Counterpoint
The conversion of preferred shares could flood the market with new common stock, triggering a sell‑off despite the current rally.
Key entities
- companyJaguar Health Inc.
Issuer of the special Series R convertible preferred stock and debtor in the deferred royalty agreements.
- companyUptown Capital
Creditor whose royalty payments to Jaguar Health are being deferred to 2027.
- companyStreeterville Capital
Creditor with a $6.22 million note whose maturity has been extended to 2027.
